Last reviewed · How we verify
Late receiving G-CSF group
Late receiving G-CSF group is a Cytokine; Hematopoietic growth factor Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently FDA-approved for Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis), Febrile neutropenia management in cancer patients.
G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to counteract chemotherapy-induced neutropenia.
G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to counteract chemotherapy-induced neutropenia. Used for Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis), Febrile neutropenia management in cancer patients.
At a glance
| Generic name | Late receiving G-CSF group |
|---|---|
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Cytokine; Hematopoietic growth factor |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | FDA-approved |
Mechanism of action
G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization. When administered after chemotherapy, it accelerates neutrophil recovery and reduces the duration and severity of neutropenia, thereby decreasing infection risk. Late receiving refers to administration after chemotherapy-induced neutropenia has already developed, rather than as primary prophylaxis.
Approved indications
- Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis)
- Febrile neutropenia management in cancer patients
Common side effects
- Bone pain
- Headache
- Fatigue
- Fever
- Splenic rupture
- Acute respiratory distress syndrome
Key clinical trials
- Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients (PHASE4)
- Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (PHASE1, PHASE2)
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients (NA)
- Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2
- Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Late receiving G-CSF group CI brief — competitive landscape report
- Late receiving G-CSF group updates RSS · CI watch RSS
- Department of Medical Services Ministry of Public Health of Thailand portfolio CI
Frequently asked questions about Late receiving G-CSF group
What is Late receiving G-CSF group?
How does Late receiving G-CSF group work?
What is Late receiving G-CSF group used for?
Who makes Late receiving G-CSF group?
What drug class is Late receiving G-CSF group in?
What development phase is Late receiving G-CSF group in?
What are the side effects of Late receiving G-CSF group?
What does Late receiving G-CSF group target?
Related
- Drug class: All Cytokine; Hematopoietic growth factor drugs
- Target: All drugs targeting G-CSF receptor (GCSFR)
- Manufacturer: Department of Medical Services Ministry of Public Health of Thailand — full pipeline
- Therapeutic area: All drugs in Oncology; Hematology
- Indication: Drugs for Chemotherapy-induced neutropenia (therapeutic/secondary prophylaxis)
- Indication: Drugs for Febrile neutropenia management in cancer patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing